Introduction: Variability in individual response profiles to antiplatelet therapy, in particular
clopidogrel, is a well-established phenomenon. Genetic variations of the cytochrome P450 …

Dual antiplatelet therapy (DAPT)—a combination of a P2Y12 receptor inhibitor and aspirin—
has revolutionized antithrombotic treatment. Potent P2Y12 inhibitors such as prasugrel and …

Aims Guided de-escalation of P2Y12-inhibitor treatment was recently identified as an
effective alternative treatment strategy in acute coronary syndrome (ACS) patients …

Background Phenotype-guided de-escalation (PGDE) of P2Y 12-inhibitor treatment with an
early switch from prasugrel to clopidogrel was identified as an effective alternative treatment …

Introduction: P2Y12 inhibitors are a critical component of dual antiplatelet therapy (DAPT),
which is the superior strategy to prevent arterialthrombosis in patients with acute coronary …

Dual antiplatelet therapy with aspirin and a P2Y12 receptor antagonist is currently the
standard of care for the prevention of ischemic events in patients with acute coronary …

Background: Prasugrel has been shown to provide more potency and less variability than
clopidogrel, but its potential temporal variability has not been described. Methods and …

Studies on platelet reactivity (PR) testing commonly test PR only after percutaneous
coronary intervention (PCI) has been performed. There are few data on pre-and post-PCI …

—Hippocrates, 460 to 370 BC (1) P2Y12 receptors on platelet membrane are key
modulators of platelet aggregation and thrombosis in acute coronary syndromes (2). Oral …

Background: The point-of-care platelet function test Plateletworks® has been shown to
identify patients with high platelet aggregation despite P2Y12 inhibition, also known as high …